A Two-open-label, Prospective, Multicentric, Phase IV Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Imeglimin Hydrochloride Tablets 500 mg and 1000 mg in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone
International Journal of Diabetes and Technology · 2026-07 · 5 (3) · 127-134
DOI: 10.4103/ijdt.ijdt_7_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Diabetes and Technology, online erschienen am 30.07.2026. Verfasst von Prashant Kumthekar und 5 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
The aim of this study was to evaluate the efficacy, safety, and tolerability of imeglimin hydrochloride tablets as monotherapy in Indian individuals with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone.
Methods
Two independent, prospective, multicentric Phase IV studies were conducted in India. One evaluated imeglimin 500 mg, and the other evaluated 1000 mg, both followed a similar 16-week monotherapy design. Primary efficacy outcomes included mean changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) from baseline to week 16. Safety was assessed by monitoring adverse events (AEs).
Results
In the imeglimin 500 mg study, HbA1c decreased by −0.72% at week 12 and −0.82% at week 16. The FPG reductions were −12.37 mg/dL at week 6, −18.70 mg/dL at week 12, and 18.86 mg/dL at week 16. The PPG decreased by −16.50 mg/dL, −27.50 mg/dL, and −26.46 mg/dL at weeks 6, 12, and 16, respectively. In the imeglimin 1000 mg study, HbA1c decreased by −0.70% at week 12 and −0.72% at week 16. The FPG reductions were −14.01 mg/dL at week 6, −16.54 mg/dL at week 12, and −16.45 mg/dL at week 16. The PPG decreased by −16.42 mg/dL, −24.79 mg/dL, and −24.32 mg/dL at weeks 6, 12, and 16, respectively. The AEs were mainly mild gastrointestinal symptoms, with no serious treatment-related events.
Conclusion
Imeglimin at doses of 500 mg or 1000 mg effectively improved glycemic parameters with good tolerability and no safety concerns in Indian individuals with T2DM.
Zitieren
APA
Kumthekar, P., Upadhyay, M., Mirajkar, S., Barge, V. B., Sharma, P. K., & Kranti, V. (2026). A Two-open-label, Prospective, Multicentric, Phase IV Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Imeglimin Hydrochloride Tablets 500 mg and 1000 mg in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone. International Journal of Diabetes and Technology, 5(3), 127-134. https://doi.org/10.4103/ijdt.ijdt_7_26
Vancouver
Kumthekar P, Upadhyay M, Mirajkar S, Barge VB, Sharma PK, Kranti V. A Two-open-label, Prospective, Multicentric, Phase IV Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Imeglimin Hydrochloride Tablets 500 mg and 1000 mg in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone. International Journal of Diabetes and Technology. 2026;5(3):127-134. doi:10.4103/ijdt.ijdt_7_26
BibTeX
@article{Kumthekar2026,
author = {Kumthekar, Prashant and Upadhyay, Mihir and Mirajkar, Sunil and Barge, Vijaykumar Bhagwan and Sharma, Prabhat Kumar and Kranti, Vijay},
title = {A Two-open-label, Prospective, Multicentric, Phase IV Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Imeglimin Hydrochloride Tablets 500 mg and 1000 mg in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone},
journal = {International Journal of Diabetes and Technology},
year = {2026},
volume = {5},
number = {3},
pages = {127--134},
doi = {10.4103/ijdt.ijdt_7_26}
}
EUVIMED